EE03099B1 - Tsüklilised iminoderivaadid, neid ühendeid sisaldavad ravimid ja meetodid nende saamiseks - Google Patents

Tsüklilised iminoderivaadid, neid ühendeid sisaldavad ravimid ja meetodid nende saamiseks

Info

Publication number
EE03099B1
EE03099B1 EE9400438A EE9400438A EE03099B1 EE 03099 B1 EE03099 B1 EE 03099B1 EE 9400438 A EE9400438 A EE 9400438A EE 9400438 A EE9400438 A EE 9400438A EE 03099 B1 EE03099 B1 EE 03099B1
Authority
EE
Estonia
Prior art keywords
compounds
preparation
drugs containing
cyclic imino
methods
Prior art date
Application number
EE9400438A
Other languages
English (en)
Inventor
Himmelsbach Frank
Austel Volkhard
Pieper Helmut
Eisert Wolfgang
Mller Thomas
Weisenberger Johannes
Linz G�nter
Kr�ger Gerd
Original Assignee
Dr. Karl Thomae Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr. Karl Thomae Gmbh filed Critical Dr. Karl Thomae Gmbh
Publication of EE03099B1 publication Critical patent/EE03099B1/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Detergent Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
EE9400438A 1990-11-02 1994-11-23 Tsüklilised iminoderivaadid, neid ühendeid sisaldavad ravimid ja meetodid nende saamiseks EE03099B1 (et)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4035961A DE4035961A1 (de) 1990-11-02 1990-11-02 Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung

Publications (1)

Publication Number Publication Date
EE03099B1 true EE03099B1 (et) 1998-06-15

Family

ID=6418111

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9400438A EE03099B1 (et) 1990-11-02 1994-11-23 Tsüklilised iminoderivaadid, neid ühendeid sisaldavad ravimid ja meetodid nende saamiseks

Country Status (25)

Country Link
US (2) US5541343A (et)
EP (1) EP0483667B1 (et)
JP (1) JP2937589B2 (et)
KR (1) KR100223135B1 (et)
AT (1) ATE163008T1 (et)
BG (1) BG62025B2 (et)
BR (1) BR1100445A (et)
CA (1) CA2054850C (et)
DE (2) DE4035961A1 (et)
DK (1) DK0483667T3 (et)
EE (1) EE03099B1 (et)
ES (1) ES2113867T3 (et)
FI (1) FI107606B (et)
GR (1) GR3026508T3 (et)
HK (1) HK1008742A1 (et)
HU (2) HUT67288A (et)
IE (1) IE913822A1 (et)
IL (1) IL99926A (et)
MX (1) MX9203677A (et)
NO (1) NO174806B (et)
NZ (1) NZ240463A (et)
PT (1) PT99402B (et)
RU (1) RU2040519C1 (et)
SG (1) SG81852A1 (et)
ZA (1) ZA918734B (et)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4127404A1 (de) * 1991-08-19 1993-02-25 Thomae Gmbh Dr K Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
AU646966B2 (en) * 1991-08-23 1994-03-10 Takeda Chemical Industries Ltd. 2-piperazinone compounds, their production and use
DK0567967T3 (da) * 1992-04-28 1996-11-18 Thomae Gmbh Dr K Tritium-mærkede fibrinogen-receptor-antagonister, deres anvendelse og fremgangsmåde til deres fremstilling
DE4213931A1 (de) * 1992-04-28 1993-11-04 Thomae Gmbh Dr K Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE4213919A1 (de) * 1992-04-28 1993-11-04 Thomae Gmbh Dr K Cyclische iminoderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE4219158A1 (de) * 1992-06-11 1993-12-16 Thomae Gmbh Dr K Biphenylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE4241632A1 (de) * 1992-12-10 1994-06-16 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5314902A (en) * 1993-01-27 1994-05-24 Monsanto Company Urea derivatives useful as platelet aggregation inhibitors
DE69425431T2 (de) * 1993-03-31 2001-02-08 Searle & Co 1-amdinophenyl-pyrrolidone/piperidinone als blutblättchen-aggregations inhibitoren
US6169107B1 (en) 1993-04-28 2001-01-02 Sumitomo Pharmaceutical Co., Ltd. Indoloylguanidine derivatives
DE4424975A1 (de) * 1994-07-15 1996-01-18 Thomae Gmbh Dr K 2-Piperidinone, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
CA2207618A1 (en) * 1994-12-23 1996-07-04 Helmut Pieper Piperazine derivatives, medicaments comprising these compounds, their use and processes for their preparation
DE69620165T2 (de) * 1995-04-26 2002-10-31 Takeda Chemical Industries Ltd Piperazinone als inhibitoren von blutplattchenaggregation
DE19515500A1 (de) * 1995-04-27 1996-10-31 Thomae Gmbh Dr K Substituierte Phenylamidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5719296A (en) * 1995-10-30 1998-02-17 Merck & Co., Inc. Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins
DE19604191A1 (de) * 1996-02-06 1997-08-07 Hoechst Schering Agrevo Gmbh 2,4-Diamino-1,3,5-triazine, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren
US5942544A (en) * 1996-02-22 1999-08-24 Dupont Pharmaceuticals Company α-branched anilines, toluenes, and analogs thereof as factor Xa inhibitors
DE19621483A1 (de) * 1996-05-29 1997-12-04 Hoechst Ag Substituierte 2-Naphthoylguanidine, Verfahren zur ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19621482A1 (de) * 1996-05-29 1997-12-04 Hoechst Ag Substituierte 1-Naphthoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
EP0934265B1 (en) * 1996-08-16 2003-01-02 Bristol-Myers Squibb Pharma Company Amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines and derivatives thereof
US6057342A (en) * 1996-08-16 2000-05-02 Dupont Pharmaceutical Co. Amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines and derivatives thereof
EP1012166B1 (en) * 1997-08-29 2003-10-29 Tularik Limited 1-amino-7-isoquinoline derivatives as serine protease inhibitors
US6740682B2 (en) 1997-08-29 2004-05-25 Tularik Limited Meta-benzamidine derivatives as serine protease inhibitors
NZ502866A (en) 1997-09-08 2001-12-21 Univ Georgetown Substituted 2-pyrrolidinone activators of PKC
KR20010032175A (ko) 1997-11-20 2001-04-16 야스이 쇼사꾸 비페닐아미딘 유도체
CA2333927A1 (en) 1998-04-01 1999-10-07 Dupont Pharmaceuticals Company Pyrimidines and triazines as integrin antagonists
WO1999052861A1 (de) * 1998-04-09 1999-10-21 Institut für Diagnostikforschung GmbH an der Freien Universität Berlin Neue benzylguanidinderivate für die therapie, in-vivo- und in-vitro-diagnostik
HUP0101137A3 (en) 1998-04-10 2003-03-28 Japan Tobacco Inc Anticoagulant amidines and their pharmaceutical use
US6518305B1 (en) 1998-04-23 2003-02-11 Abbott Laboratories Five-membered carbocyclic and heterocyclic inhibitors of neuraminidases
US6455571B1 (en) 1998-04-23 2002-09-24 Abbott Laboratories Inhibitors of neuraminidases
TR200003065T2 (tr) * 1998-04-23 2001-02-21 Abbott Laboratories Nöraminidazların inhibitörleri olarak pirolidinler.
DE69917201T2 (de) 1998-07-22 2005-05-04 Daiichi Suntory Pharma Co., Ltd. Nf-kappa b inhibitoren, die indanderivate als aktiven bestandteil enthalten
US6284796B1 (en) * 1998-08-06 2001-09-04 Abbott Laboratories Ukokinase inhibitors
DE19844787A1 (de) * 1998-09-30 2000-04-13 Boehringer Ingelheim Pharma Disubstituierte Pyrrolidinone, diese Verbindung enthaltende Arzneimittel und deren Verwendung sowie ihre Herstellung
AU3389300A (en) 1999-03-02 2000-09-21 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
AU3386500A (en) 1999-03-02 2000-09-21 Merck & Co., Inc. 3-cyclopropyl and 3-cyclobutyl pyrrolidine modulators of chemokine receptor activity
CA2360740A1 (en) 1999-03-02 2000-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cathepsin s
WO2000051609A1 (en) * 1999-03-02 2000-09-08 Merck & Co., Inc. 3-alkyl substituted pyrrolidine modulators of chemokine receptor activity
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
FR2817257B1 (fr) * 2000-11-30 2009-03-20 Sanofi Synthelabo Cyclohexyl(alkyl)-propanolamines, leur preparation et compositions pharmaceutiques en contenant
EP1358178A2 (en) * 2001-01-30 2003-11-05 Bristol-Myers Squibb Company Sulfonamide lactam inhibitors of factor xa
DE10121003A1 (de) * 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
GB0114005D0 (en) 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
GB0114004D0 (en) 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
TWI224101B (en) * 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
PT1397130E (pt) * 2001-06-20 2007-11-13 Wyeth Corp Derivados ácidos de indole substituído como inibidores de inibidor 1 do activador de plasminogénio (pai-1)
US7348351B2 (en) * 2002-12-10 2008-03-25 Wyeth Substituted 3-alkyl and 3-arylalkyl 1H-indol-1yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
AU2003296324A1 (en) * 2002-12-10 2004-06-30 Wyeth Aryl, aryloxy, and alkyloxy substituted 1h-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
UA80453C2 (en) * 2002-12-10 2007-09-25 Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
DK1569900T3 (da) * 2002-12-10 2006-10-23 Wyeth Corp Substituerede 3-carbonyl-1-yl-eddikesyrederivater som inhibitorer af plasminogenaktivator-inhibitor-1 (PAI-1)
CA2515266A1 (en) * 2003-02-07 2004-08-19 Boehringer Ingelheim International Gmbh Use of dipyridamole or mopidamole for treatment and prevention of mmp-9-dependent disorders
WO2004093881A2 (en) 2003-04-24 2004-11-04 Boehringer Ingelheim International Gmbh Use of dipyridamole or mopidamole for treatment and prevention of thrombo-embolic diseases and disorders caused by excessive formation of thrombin and/or by elevated expression of thrombin receptors
CA2525841C (en) * 2003-05-16 2012-10-16 Merck Sharp & Dohme Limited Cyclohexyl sulphones as gamma-secretase inhibitors
US7163954B2 (en) * 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
US7351726B2 (en) * 2003-09-25 2008-04-01 Wyeth Substituted oxadiazolidinediones
US7420083B2 (en) * 2003-09-25 2008-09-02 Wyeth Substituted aryloximes
US7442805B2 (en) * 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
US7582773B2 (en) * 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
US7141592B2 (en) * 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
US7534894B2 (en) 2003-09-25 2009-05-19 Wyeth Biphenyloxy-acids
US7268159B2 (en) * 2003-09-25 2007-09-11 Wyeth Substituted indoles
US7342039B2 (en) * 2003-09-25 2008-03-11 Wyeth Substituted indole oximes
US7332521B2 (en) * 2003-09-25 2008-02-19 Wyeth Substituted indoles
US7411083B2 (en) 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
US7265148B2 (en) * 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US7446201B2 (en) * 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids
US7759387B2 (en) 2003-10-08 2010-07-20 Piramal Life Sciences Limited Fibrinogen receptor antagonists and their use
EP1720847A1 (en) * 2004-02-02 2006-11-15 Pfizer Products Incorporated Histamine-3 receptor modulators
EA011097B1 (ru) * 2004-05-07 2008-12-30 Янссен Фармацевтика Н.В. Производные пирролидин-2-она и пиперидин-2-она, используемые в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы
BRPI0514544A (pt) * 2004-08-23 2008-06-17 Wyeth Corp ácidos de oxazol-naftila como moduladores de inibidor tipo-1 de ativador de plasminogênio (pai-1)
JP2008510816A (ja) * 2004-08-23 2008-04-10 ワイス チアゾロ−ナフチル酸
CA2577782A1 (en) * 2004-08-23 2006-03-02 Wyeth Pyrrolo-naphthyl acids as pai-1 inhibitors
US8563591B2 (en) * 2004-08-30 2013-10-22 Janssen Pharmaceutica N.V. Tricyclic lactam derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
MY146435A (en) * 2004-08-30 2012-08-15 Janssen Pharmaceutica Nv N-2 adamantanyl-2-phenoxy-acetamide derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
DE602005017159D1 (de) 2004-08-30 2009-11-26 Janssen Pharmaceutica Nv Oxysteroid-dehydrogenase-inhibitoren
WO2006114096A1 (en) * 2005-04-25 2006-11-02 Danmarks Tekniske Universitet Pyrrolidinone dipeptide analogs and use thereof as artificial sweeteners
US7683091B2 (en) * 2005-08-17 2010-03-23 Wyeth Substituted indoles and methods of their use
MX337100B (es) * 2007-10-05 2016-02-11 Acucela Inc Compuestos alcoxi para el tratamiento de enfermedades.
NZ585103A (en) * 2007-10-23 2012-04-27 Allergan Inc Substituted lactams derivatives and their uses for glaucoma and ocullar hypertension
WO2011003103A2 (en) 2009-07-02 2011-01-06 Acucela, Inc. Pharmacology of visual cycle modulators
US8822679B2 (en) * 2011-06-24 2014-09-02 California Institute Of Technology Quaternary heteroatom containing compounds
US20130267699A1 (en) 2011-06-24 2013-10-10 California Institute Of Technology Quaternary heteroatom containing compounds
US9518034B2 (en) 2013-10-14 2016-12-13 California Institute Of Technology Synthesis of chiral enaminones, their derivatives, and bioactivity studies thereof
JP6431538B2 (ja) 2013-11-21 2018-11-28 マーケット ユニバーシティー エストロゲン受容体ベータアイソフォームの選択的アゴニストとしての置換（４’−ヒドロキシフェニル）シクロアルカン化合物およびその使用
US10421696B2 (en) 2014-12-18 2019-09-24 California Institute Of Technology Enantioselective synthesis of α-quaternary mannich adducts by palladium-catalyzed allylic alkylation
US10106479B2 (en) 2015-03-27 2018-10-23 California Institute Of Technology Asymmetric catalytic decarboxylative alkyl alkylation using low catalyst concentrations and a robust precatalyst
US10040784B2 (en) 2016-03-11 2018-08-07 California Institute Of Technology Compositions and methods for acylating lactams
EP3480190B1 (en) 2017-11-01 2023-01-04 California Institute of Technology Methods for enantioselective allylic alkylation of esters, lactones, and lactams with unactivated allylic alcohols
US11214568B2 (en) 2018-10-18 2022-01-04 California Institute Of Technology Gem-disubstituted pyrrolidines, piperazines, and diazepanes, and compositions and methods of making the same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4247466A (en) * 1979-07-05 1981-01-27 American Cyanamid Company Lactone metabolites of 3-(4-biphenylylcarbonyl)propionic acid
EP0194548A3 (de) * 1985-03-12 1988-08-17 Dr. Karl Thomae GmbH Neue Sulfonylaminoäthylverbindungen, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
ATE80611T1 (de) * 1985-03-16 1992-10-15 Wellcome Found Aryl-derivate.
DE3823299A1 (de) * 1988-07-07 1990-01-11 Schering Ag Substituierte phenyl-pyrrolidin-2-one, -oxazolidin-2-one und -imidazolidin-2-one, ihre herstellung sowie verwendung in arzneimitteln

Also Published As

Publication number Publication date
GR3026508T3 (en) 1998-07-31
BR1100445A (pt) 2000-07-18
PT99402B (pt) 1999-04-30
NO174806C (et) 1994-07-13
IL99926A0 (en) 1992-08-18
NO914294L (no) 1992-05-04
DK0483667T3 (da) 1998-09-23
DE4035961A1 (de) 1992-05-07
SG81852A1 (en) 2001-07-24
ES2113867T3 (es) 1998-05-16
FI915136A (fi) 1992-05-03
EP0483667A2 (de) 1992-05-06
NZ240463A (en) 1997-04-24
JPH04264068A (ja) 1992-09-18
AU650488B2 (en) 1994-06-23
MX9203677A (es) 1992-07-01
HU913455D0 (en) 1992-01-28
EP0483667A3 (en) 1992-09-16
KR920009793A (ko) 1992-06-25
PT99402A (pt) 1992-09-30
IL99926A (en) 1996-06-18
FI107606B (fi) 2001-09-14
DE59108930D1 (de) 1998-03-12
KR100223135B1 (ko) 1999-10-15
IE913822A1 (en) 1992-05-22
HU211563A9 (en) 1995-12-28
JP2937589B2 (ja) 1999-08-23
NO174806B (no) 1994-04-05
US5541343A (en) 1996-07-30
ATE163008T1 (de) 1998-02-15
CA2054850C (en) 2001-01-02
HK1008742A1 (en) 1999-05-14
RU2040519C1 (ru) 1995-07-25
US5591769A (en) 1997-01-07
CA2054850A1 (en) 1992-05-03
NO914294D0 (no) 1991-11-01
EP0483667B1 (de) 1998-02-04
BG62025B2 (bg) 1998-12-30
HUT67288A (en) 1995-03-28
AU8692691A (en) 1992-05-07
ZA918734B (en) 1993-05-04
FI915136A0 (fi) 1991-10-31

Similar Documents

Publication Publication Date Title
EE03099B1 (et) Tsüklilised iminoderivaadid, neid ühendeid sisaldavad ravimid ja meetodid nende saamiseks
FI923691A (fi) Cykliska iminoderivat, dessa foereningar innehaollande farmaceutiska blandningar och foerfarande foer deras framstaellning
FI931880A (fi) Cykliska iminoderivat, foerfarande foer deras framstaellning och dessa foereningar innehaollande laekemedel
NO177852C (no) Bifenylderivater, legemidler inneholdende disse, og anvendelse av dem for fremstilling av legemidler

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20121123